Title |
Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis
|
---|---|
Published in |
Cochrane database of systematic reviews, July 2013
|
DOI | 10.1002/14651858.cd007168.pub3 |
Pubmed ID | |
Authors |
Julian Tam, Edward F Nash, Felix Ratjen, Elizabeth Tullis, Anne Stephenson |
Abstract |
Cystic fibrosis is an inherited condition resulting in thickened, sticky respiratory secretions. Respiratory failure, due to recurrent pulmonary infection and inflammation, is the most common cause of mortality. Muco-active therapies (e.g. dornase alfa and nebulized hypertonic saline) may decrease sputum viscosity, increase airway clearance of sputum, reduce infection and inflammation and improve lung function. Thiol derivatives, either oral or nebulized, have shown benefit in other respiratory diseases. Their mode of action is likely to differ according to the route of administration. There are several thiol derivatives, and it is unclear which of these may be beneficial in cystic fibrosis. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 2 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Brazil | 1 | <1% |
Unknown | 144 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 19 | 13% |
Student > Ph. D. Student | 16 | 11% |
Researcher | 15 | 10% |
Student > Bachelor | 13 | 9% |
Other | 9 | 6% |
Other | 28 | 19% |
Unknown | 45 | 31% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 55 | 38% |
Pharmacology, Toxicology and Pharmaceutical Science | 10 | 7% |
Nursing and Health Professions | 9 | 6% |
Agricultural and Biological Sciences | 5 | 3% |
Biochemistry, Genetics and Molecular Biology | 4 | 3% |
Other | 13 | 9% |
Unknown | 49 | 34% |